RCMNet: A deep learning model assists CAR-T therapy for leukemia
Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved, the risk of recurrence is still high. Therefore, novel treatme...
Gespeichert in:
Veröffentlicht in: | Computers in biology and medicine 2022-11, Vol.150, p.106084, Article 106084 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved, the risk of recurrence is still high. Therefore, novel treatments are demanding. Chimeric antigen receptor-T (CAR-T) therapy has emerged as a promising approach to treating and curing acute leukemia. To harness the therapeutic potential of CAR-T cell therapy for blood diseases, reliable cell morphological identification is crucial. Nevertheless, the identification of CAR-T cells is a big challenge posed by their phenotypic similarity with other blood cells. To address this substantial clinical challenge, herein we first construct a CAR-T dataset with 500 original microscopy images after staining. Following that, we create a novel integrated model called RCMNet (ResNet18 with Convolutional Block Attention Module and Multi-Head Self-Attention) that combines the convolutional neural network (CNN) and Transformer. The model shows 99.63% top-1 accuracy on the public dataset. Compared with previous reports, our model obtains satisfactory results for image classification. Although testing on the CAR-T cell dataset, a decent performance is observed, which is attributed to the limited size of the dataset. Transfer learning is adapted for RCMNet and a maximum of 83.36% accuracy is achieved, which is higher than that of other state-of-the-art models. This study evaluates the effectiveness of RCMNet on a big public dataset and translates it to a clinical dataset for diagnostic applications.
The Peripheral Blood Cells (PBC) dataset is used to train our RCMNet model. Blood samples are collected from patients receiving CAR-T therapy. The Cells are stained by May Grünwald-Giemsa for wide field image acquisition. RCMNet is transferred from PBC dataset to our CAR-T cell dataset. [Display omitted]
•The first dataset for CAR-T cell and non-CAR-T cell classification.•A deep neural network (RCMNet) consisting of CNN and self-attention for classification tasks.•Enhance performance of RCMNet on CAR-T dataset by transfer learning.•RCMNET performs well in identifying CAR-T cell, which shows the potential to aid in clinical decision-making. |
---|---|
ISSN: | 0010-4825 1879-0534 1879-0534 |
DOI: | 10.1016/j.compbiomed.2022.106084 |